Navigation
banner

Biomarker Summit

2017-11-212017-12-272017-11-27
EARLY BIRD DISCOUNT! Register by Nov 27, 2017 to receive 30% off your registration!
Or Register 3 for the price of 2 with the coupon code rcdvb!


registration button

Subscribe for updates




Dear Colleague,

The Biomarker Summit 2018, to be held on March 27-28, 2018 in San Diego, CA at the Omni San Diego Hotel, is a meeting place for leaders in the field to discuss the issues and challenges scientists and researchers face in all aspects of the biomarker and diagnostic development process from discovery to translation to commercialization.

Topics to be covered:

A wide variety of important topics will be covered including biomarker identification, validation, and translation strategies, bioinformatics and systems biology approaches to personalized medicine, big data analytics and management, regulatory and reimbursement trends, companion diagnostics development, and much more. Through scientific presentations, case studies and panel discussions, these areas will be addressed in an intimate and highly interactive environment with perspectives from industry, academia and the public sector.

Assembling leading scientists, researchers, decision-makers and other players across the industry spectrum, the Summit provides a unique opportunity to gain the latest biomarker developments in four major therapeutic areas, formally organized in the following tracks:

Joint Plenary Sessions:

  1. Opening Keynote Session – Historical Perspective & Current State of the Industry
  2. Round Table Discussions 
  3. Lunch Session: Big Data Analytics & Bioinformatics for Biomarkers Development
  4. Award Ceremony & Closing Keynote Session – Predictions for future

Oncology Biomarkers

  1. Immuno-Oncology Biomarkers
  2. Circulating Tumor Cells, Microvesicles, DNA and RNA

Neurological Biomarkers

  1. Biomarkers for Early Identification of Neurological Disease
  2. Monitoring Progression and Treatment Efficacy using Biomarkers

Inflammatory & Immunological Biomarkers

  1. Biomarkers for Early Progressive Inflammatory & Immunological Diseases
  2. Biomarkers as Surrogate Endpoints for Clinical Trials

Cardiovascular Biomarkers

  1. Biomarkers for Heart Failure & Acute Coronary Syndrome
  2. Biomarkers for Metabolic Syndrome & Cardiovascular Risk

 

We hope to see you there!

Best regards,

The 2018 Advisory Committee

 
2018 ADVISORY BOARD MEMBERS
Andreas Jeromin, Quanterix
Andrew Penn, Victoria General Hospital
Bruce W.M.Jordan, Roche Diagnostics
Cristina Stefan, Roche
Daniel Chelsky, Caprion Biosciences
Frédéric Baribaud, Janssen
Gary Gustavsen, Health Advances
Mark Frasier, Michael J. Fox Foundation
Michael Heller, University of California, San Diego
Parag Mallick, Stanford University
Pierluigi Mauri, Proteomics and Metabolomics Laboratory – CNR, Institute for Biomedical Tecnologies (ITB-CNR)
Stephen Pennington, University College Dublin